Eledon Pharmaceuticals, Inc.
ELDN
$1.59
$0.117.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.97% | 36.98% | 46.62% | 44.29% | 17.52% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.80% | 87.40% | 81.65% | 64.13% | 31.65% |
| Operating Income | -53.80% | -87.40% | -81.65% | -64.13% | -31.65% |
| Income Before Tax | -266.27% | 113.89% | 85.61% | 69.32% | 85.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -268.26% | 113.49% | 85.28% | 68.95% | 85.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -268.26% | 113.49% | 85.28% | 68.95% | 85.04% |
| EBIT | -53.80% | -87.40% | -81.65% | -64.13% | -31.65% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 24.42% | 129.83% | 94.14% | 79.51% | 82.40% |
| Normalized Basic EPS | 20.29% | 119.42% | 93.99% | 79.37% | 69.70% |
| EPS Diluted | 70.65% | 69.48% | 49.00% | 34.06% | 54.68% |
| Normalized Diluted EPS | 25.43% | 116.45% | 92.06% | 77.42% | 67.62% |
| Average Basic Shares Outstanding | 94.82% | 108.25% | 111.96% | 97.87% | 87.44% |
| Average Diluted Shares Outstanding | 90.47% | 110.91% | 115.06% | 101.47% | 91.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |